Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated...

Area of Science:

• Hematology
• Molecular Biology
• Cancer Genetics

Background:

• Acute myeloid leukemia (AML) pathogenesis involves complex gene mutation interactions.
• NPM1 mutations are common in AML, often co-occurring with cohesin complex mutations.
• Understanding these combinatorial mutations is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate how cohesin mutations affect the transcriptome in the context of NPM1 mutations in AML.
• To identify specific molecular pathways altered by the combined NPM1 and cohesin mutations.
• To explore potential therapeutic targets arising from these specific AML mutational contexts.

Main Methods:

• Utilized inducible mouse models (Npm1^cAflox/+ and Smc3^flox/+) for AML development studies.
• Performed RNA sequencing (RNA-seq) to analyze transcriptomic alterations.
• Conducted gene knockdown experiments (Dock1) and measured downstream effects on cell behavior and pathway activity (Rac).

Main Results:

• The NPM1^cA/+;Smc3^Δ/+ mutational combination uniquely altered the transcriptome compared to NPM1^cA/+ alone.
• Dock1, a Rac1/2 nucleotide exchange factor, was specifically upregulated in NPM1^cA/+;Smc3^Δ/+ hematopoietic stem and progenitor cells (HSPCs).
• Dock1 knockdown in NPM1^cA/+;Smc3^Δ/+ AML led to decreased growth, adhesion, and increased apoptosis, with elevated Rac activity observed.

Conclusions:

• The Dock1/Rac pathway is specifically activated in AML with combined NPM1 and cohesin mutations.
• Targeting the Dock1/Rac pathway presents a potential therapeutic strategy for AML patients with NPM1cA and cohesin mutations.
• Combinatorial genetic analysis is valuable for discovering novel precision oncology targets.